Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACYW135X meningococcal conjugate vaccine - Sinovac Biotech

Next Previous
Drug Profile

ACYW135X meningococcal conjugate vaccine - Sinovac Biotech

Alternative Names: ACYW135X meningococcal conjugate vaccine-Sinovac Biotech; Meningococcal vaccine groups A,C,W-135, Y, X conjugate - Sinovac Biotech

Latest Information Update: 03 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinovac Biotech
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Meningococcal infections

Most Recent Events

  • 28 Jan 2026 Preclinical trials in Meningococcal infections in China (Parenteral) prior to January 2026
  • 28 Jan 2026 Sinovac Biotech plans a phase I trial for Meningococcal infections (Prevention, In children, In adolescents, In adults) in unknown location (Parenteral) in January 2026 (NCT07374510)
  • 18 Dec 2023 Sinovac Biotech has patent pending for a pentavalent Neisseria meningitidis conjugate vaccine and its preparation method and application in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top